Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VT-1598 in Healthy Adults
NCT04208321Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VT-1598 in coccidioidomycosis (6 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Unsolicited Adverse Events, Number of Participants With Abnormal Chemistry, Hematology, Coagulation, and Urinalysis Laboratory Toxicity Results and 2 more. Started Sep 2020; status: completed.
02
Drugs
VT-1598
03
Conditions
coccidioidomycosis
Beyond the preview
Go deeper on NCT04208321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208321.